ISSN: 2167-065X
Clinical Pharmacology & Biopharmaceutics
Open Access
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)Useful Links
Recommended Journals
Additional Info
Loading Please wait..
H2S-based drug development and delivery
2nd International Summit on Clinical Pharmacy
December 02-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA
| Rui Wang |
| Accepted Abstracts: Clinic Pharmacol Biopharm |
| DOI: 10.4172/2167-065X.S1.008 |
| Abstract |
| More than a toxin generated in chemistry industry and from environmental pollution, hydrogen sulfide (H2S) is also produced in our bodies with L-cysteine and homocysteine as the endogenous substrate. Over the last decade, the physiological importance of H2S has been demonstrated in numerous human body systems, including the cardiovascular and respiratory, neuronal, endocrinal, gastrointestinal, reproductive, liver, kidney and urinary systems. Altered metabolism and functions of H2S constitutes a critical factor for the pathogenesis of a number of human diseases, such as hypertension, atherosclerosis, heart failure and stroke, diabetes, asthma, neurodegenerative diseases, gastrointestinal inflammation, cancer, etc. In recent years, multiple lines of H2S-based drugs (organic and inorganic H2S-donors or hybrid molecules) have been developed for different clinical situations. Fast-releasing H2S donors, such as NaHS and Na2S, offer the tool to quickly correct H2S deficiency under specific pathological conditions, e.g. ischemic/reperfusion heart failure. Slow-releasing H2S donors, such as GYY4137, provide sustained protection against H2S-related chronic diseases. Mitochondria-targeted H2S donors, such as AP39, have the potential to directly optimize mitochondrial energy production and oxidant/antioxidant balance. These novel approaches have been successful in animal studies and being tested clinically at different trial stages. With improved delivery methods and organ- and cell type-specific releasing mechanism for H2S release, H2S-based drug development opens new horizon for improving the efficiency and potency, decreasing the side effect, minimizing the disturbance of system homeostasis of the next generation of drugs. (Supported by an operating grant from Canadian Institutes of Health Research) |
 PDF |  HTML |
Relevant Topics
- Applied Biopharmaceutics
- Biopharmaceuticals Manufacturing and Industry
- Biopharmaceuticals Process Validation
- Biopharmaceutics and Drug Disposition
- Clinical Drug Trials
- Clinical Pharmacists
- Clinical Pharmacology
- Clinical Research Studies
- Clinical Trials Databases
- Drug Side Effect
- Medical Trails/ Drug Medical Trails
- Methods in Clinical Pharmacology
- Molecular Pharmacology
- Neuropharmacology
- Pharmacoeconomics
- Pharmacoepidemiology
- Pharmacogenomics
- Pharmacokinetics
- Pharmacotherapeutics
- Preclinical safety evaluation of biopharmaceuticals
- Psychopharmacology
- Systems Pharmacology
- Theoretical Pharmacology
